JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$253.96
−0.63%Oct 19, 2026, 12:00 UTC
JOHNSON & JOHNSON announced Phase 3 FUZION study results showing TREMFYA maintained or improved fistula remission through Week 48 in adults with Crohn’s disease; remission in the 100 mg dose group increased from 28% at Week 24 to 35% at Week 48.
Source:Oct 14, 2026, 16:01 UTC
JOHNSON & JOHNSON shares fell 5.8% after its third-quarter earnings report.
Source:Oct 14, 2026, 01:07 UTC
JOHNSON & JOHNSON shares fell more than 5% on Tuesday.
Source:Oct 13, 2026, 21:30 UTC
JOHNSON & JOHNSON raised its full-year forecast on October 13, 2026.
Source:Oct 13, 2026, 18:23 UTC
JOHNSON & JOHNSON shares were heading for their worst daily decline in more than 18 months.
Source:Oct 13, 2026, 16:31 UTC
JOHNSON & JOHNSON weighed a possible orthopedics spinoff.
Source:Oct 13, 2026, 16:01 UTC
JOHNSON & JOHNSON reported third-quarter earnings above estimates but sales below expectations, with MedTech lagging.
Source:Oct 13, 2026, 15:07 UTC
JOHNSON & JOHNSON shares moved as the company reported earnings and raised its profit guidance.
Source:Oct 13, 2026, 12:47 UTC
JOHNSON & JOHNSON reported quarterly earnings of $2.59 per share, compared with $2.80 per share a year earlier.
Source:Oct 13, 2026, 10:37 UTC
JOHNSON & JOHNSON is reportedly inclined to spin off its hip and knee business.
Oct 13, 2026, 10:25 UTC
JOHNSON & JOHNSON set its quarterly dividend at $1.34 per share, unchanged from its previous regular cash dividend.
Oct 12, 2026, 20:05 UTC
JOHNSON & JOHNSON announced new Phase 3 JOHNSON & JOHNSON subgroup data showing consistent combined fistula remission outcomes with TREMFYA across clinically important subgroups of adults with Crohn’s disease and perianal fistula.
Source:Oct 12, 2026, 20:05 UTC
JOHNSON & JOHNSON announced three-year Phase 3 GALAXI 2 and 3 study data showing sustained clinical and endoscopic remission with TREMFYA in adults with moderately to severely active Crohn's disease, including clinical remission rates of up to 94%, endoscopic remission rates of up to 61%, and 90-day corticosteroid-free clinical remission in 88% of patients.
Source:Oct 9, 2026, 11:00 UTC
JOHNSON & JOHNSON announced new two-year Phase 3 JOHNSON & JOHNSON study results for ICOTYDE in adults and adolescents with plaque psoriasis, with nearly three-quarters achieving clear or almost clear skin and a continued favorable safety profile.
Source:Oct 9, 2026, 03:13 UTC
SanegeneBio and its wholly owned subsidiary SanegeneBio (Shanghai) signed a collaboration and license agreement with JOHNSON & JOHNSON to jointly develop novel oral medicines.
Source:Oct 4, 2026, 15:30 UTC
Oxford Science Enterprises appointed Dr Jeffrey Moore as senior partner and head of life sciences, succeeding Katya Smirnyagina, who will remain as an advisor.
Source:Oct 2, 2026, 10:00 UTC
Johnson & Johnson announced new two-year Phase 3 ICONIC-TOTALa data showing ICOTYDE (icotrokinra) achieved sustained skin clearance in patients with high-impact plaque psoriasis.
Source:Sep 29, 2026, 12:03 UTC
Johnson & Johnson announced new two-year findings on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis across 15 abstracts to be presented at the 2026 MGFA Scientific Session and AANEM Annual Meeting.
Source:Sep 27, 2026, 11:45 UTC
A UAE delegation led by Minister of Health and Prevention Ahmed bin Ali Al Sayegh visited healthcare and academic institutions in Boston and New York to explore strategic partnerships in genomic medicine, AI, digital health, rare diseases and specialised care.
Source:Sep 25, 2026, 15:03 UTC
Johnson & Johnson announced positive findings from clinical evaluations of its therapies Tremfya and Carvykti in psoriatic arthritis and multiple myeloma.
Source:Sep 25, 2026, 11:30 UTC
Johnson & Johnson announced that TREMFYA met its primary and key secondary endpoints in a study of axial psoriatic arthritis.
Sep 25, 2026, 11:02 UTC
Johnson & Johnson announced that CARVYKTI achieved five-year treatment-free remission in 50% of patients with early relapsed or refractory multiple myeloma.
Sep 23, 2026, 17:45 UTC
AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.
Source:Sep 23, 2026, 14:17 UTC
Johnson & Johnson reported new data from the Phase 3 MAJESTEC-3 study.
Source:Sep 23, 2026, 13:49 UTC
Johnson & Johnson announced that its TECVAYLI combined with DARZALEX FASPRO regimen reduces the risk of disease progression in multiple myeloma by 90% versus standard therapy.
Sep 21, 2026, 12:50 UTC
Johnson & Johnson announced that its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, advancing the drug toward expanded approval.
Sep 18, 2026, 01:58 UTC
Johnson & Johnson's Abiomed unit is removing every Automated Impella Controller worldwide to replace parts linked to failures associated with 37 serious injuries and three deaths, per an FDA early alert.
Source:Sep 17, 2026, 21:18 UTC
PepsiCo appointed Joaquin Duato, Johnson & Johnson's Chairman and CEO, as an independent member of its Board effective December 1, 2026.
Sep 14, 2026, 01:58 UTC
Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's DePuy Synthes orthopedics business for around $20 billion.
Source:Sep 9, 2026, 23:30 UTC
Johnson & Johnson secured Chinese regulatory approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis, expanding its psoriasis portfolio in China.
Source:
Page 1Next →